Utility of the neutrophil/lymphocyte ratio for predicting malignancy risk and prognosis in patients with dermatomyositis. Galadari AA, Sun LD, Fernandez AP. Clin Exp Dermatol 2020;45:471-473.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Galadari AA, Sun LD, Fernandez AP. Utility of the neutrophil/lymphocyte ratio for predicting malignancy risk and prognosis in patients with dermatomyositis. Clin Exp Dermatol 2020;45:471-473.
PMID: 31692021